Skip to main content
. 2018 Dec 17;9:1480. doi: 10.3389/fphar.2018.01480

FIGURE 4.

FIGURE 4

Length of pirfenidone treatment prior to discontinuation due to ADRs, stratified according to baseline pulmonary function. The duration of pirfenidone therapy was examined in patients who had discontinued treatment due to ADRs and was then stratified according to their baseline FVC (% predicted) and TLCO (% predicted). Data was available for 40/46 patients. Those with a baseline FVC < 65% predicted (n = 13) had significantly shorter length of treatment prior to discontinuation of therapy due to ADRs compared to those with FVC % predicted 65–80% (n = 16) (∗p < 0.05). There was no significant difference in duration of therapy when stratified according to baseline TLCO % predicted. Data presented as means with standard deviation. Statistical analysis: analysis of variance with post hoc Holm’s–Sidak comparisons analysis. FVC, forced vital capacity; NICE criteria, National Institute for Health and Care excellence criteria for stopping medication (National Institute for Health and Care Excellence, 2013) (anti-fibrotic medication has to be stopped where there is disease progression as evidenced by a decline in percent predicted FVC of 10% or more within any 12 months period).